Ignite Creation Date:
2024-05-06 @ 2:48 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04433156
Status:
RECRUITING
Last Update Posted:
2023-05-18
First Post:
2020-06-11
Brief Title:
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
A Single Arm Multi-center Phase II Clinical Trial of VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single arm multi-center phase II clinical trial to observe the efficacy and safety of VR-CAP Bortezomib and Rituximab-Cyclophosphamide Epirubicin and Prednisone in the first-line treatment for patients with marginal zone lymphoma
Detailed Description:
Marginal zone lymphoma MZL is a relatively common group of non-Hodgkins lymphoma NHL The incidence rate is only inferior to diffuse large B cell lymphoma DLBCL and follicular lymphoma FL Currently NCCN guidelines recommend same treatment plan of FL like R-CHOP as the primary treatment for MZL However due to the great difference in cell origin and biological characteristics between FL and MZL some patients can not achieve complete remission or relapse quickly after standard first-line treatment A number of phase II clinical studies have evaluated the good efficacy of rituximab combined with chemotherapy in the treatment of MZL Previous studies have shown that NF-κB signaling pathway is in abnormal activation state in MZL Bortezomib a proteasome inhibitor targeting NF-κB pathway has a promising therapeutic prospect in relapsed and refractory MZL The goal of our trial is to assess the efficacy and safety of VR-CAP Bortezomib and Rituximab-Cyclophosphamide Epirubicin and Prednisone in the first-line treatment for patients with marginal zone lymphoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None